Edgewise Therapeutics (EWTX) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Legend Biotech (LEGN) over the past year, gaining 161.4% versus a loss of 39.1%. Over five years, EWTX leads with a +123.1% price change compared with -63.2% for LEGN. Edgewise Therapeutics is the larger company by market cap ($4.30 billion vs $3.72 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | LEGN |
|---|---|---|
| Share price | $39.57 | $19.12 |
| Market cap | $4.30B | $3.72B |
| 1-day change | -1.12% | +2.14% |
| YTD return | +59.46% | -12.05% |
| 1-year return | +161.36% | -39.13% |
| 5-year return | +123.06% | -63.17% |
| Forward P/E | — | 18.21 |
| EPS (TTM) | $-1.86 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.03B |
| Revenue growth (YoY) | — | +64.04% |
| Net income (latest FY) | $-167.79M | $-296.80M |
| Gross margin | — | 61.41% |
| Operating margin | — | -13.27% |
| Net margin | — | -28.85% |
| 52-week high | $48.51 | $37.50 |
| 52-week low | $14.25 | $16.24 |
| Distance from 52-week high | -18.43% | -49.01% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +32.98% | +143.20% |
| Average volume | 1.35M | 2.37M |
| Shares outstanding | 108.60M | 194.49M |
| Employees | 127 | 3,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed LEGN by 200.5 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
EWTX vs LEGN FAQ
Which is bigger, Edgewise Therapeutics or Legend Biotech?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.30B compared with $3.72B for Legend Biotech (LEGN).
Which stock has performed better over the past year, EWTX or LEGN?
EWTX returned +161.36% over the past 12 months, compared with -39.13% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Legend Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.